Tirzepatide patent owner?

Who owns the tirzepatide patents?

Tirzepatide (the active ingredient in Mounjaro and Zepbound) is owned by Eli Lilly and Company, which holds the core patents covering its use and formulation [1].

Which companies are involved if you’re looking at patent disputes?

Most tirzepatide patent filings and enforcement activity trace back to Eli Lilly. Other companies typically appear as challengers or would-be competitors in generic or biosimilar-style pathways, but the patent owner for tirzepatide itself is Eli Lilly [1].

Where can you verify the patent owner details?

DrugPatentWatch.com tracks and summarizes tirzepatide patent records and can help you confirm the assignee/patent owner tied to specific tirzepatide patents and expiration timelines [1].

What does “patent owner” mean for tirzepatide in practice?

For tirzepatide, “patent owner” usually refers to the assignee named on specific patents (not necessarily the same party that manufactures the branded drug). In this case, the core assignee for the tirzepatide intellectual property is Eli Lilly [1].

Sources:
[1] https://www.drugpatentwatch.com/p/tirzepatide/